Navigation Links
Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Date:4/6/2009

COSTA MESA, Calif., April 6 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced today that company Chairman and CEO, Chris Stern, has posted a new entry on his blog on the company website. The latest blog discusses the company's recent meetings in Zurich, Switzerland, further development plans for Oxycyte(R) in indications beyond traumatic brain injury, supply plans for clinical-grade Oxycyte, and plans for raising additional capital.

The blog is available on the company's Electronic Shareholder Forum which can be found via the Investor Relations page of the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
2. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
3. Oxygen Biotherapeutics, Inc. Expands Board of Directors
4. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
5. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
6. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
7. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
8. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
9. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
10. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Bacterial biofilms, surface adherent communities of bacteria that ... ranging from food poisoning and catheter infections to gum disease and the rejection of ... billions of dollars per year, there is currently a paucity of means for preventing ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and pathology ... B2 at the Association for Pathology Informatics Annual Summit at the ... demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it ...
(Date:5/18/2017)... , ... May 18, 2017 , ... ... on April 28, 2017 at the Prince Of Wales Private Hospital. The procedure ... at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , ...
(Date:5/18/2017)... ... May 17, 2017 , ... Cognition Corporation ( ... just released version 9.0 of the Cognition Cockpit platform. , “Our whole team ... David Cronin, CEO of Cognition. “We’re thrilled to finally be able to release ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a new ... Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, ... IAM Market is expected to grow from USD 14.30 Billion in 2017 ... (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):